Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 34.01 CNY -1.13%
Market Cap: 26.2B CNY
Have any thoughts about
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

30.6
Current
30.4
Median
13.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
30.6
=
Enterprise Value
24.3B CNY
/
EBITDA
793.9m CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
15.9
2-Years Forward
EV/EBITDA
13.5
3-Years Forward
EV/EBITDA
11.7

See Also

Discover More